27 September 2017 EMA/68528/2014 CORRECTION 4* Patient Health Protection
List of flupirtine-containing medicinal products in the European Union Name of the product
Marketing Authorisation Holder
Country where product is authorised
Katadolon
Teva Pharma B.V.
Estonia
Flupirtinmaleat AbZ 100 mg Kapseln
AbZ-Pharma GmbH
Germany
Flupirtinmaleat AL 100 mg Hartkapseln
Aliud Pharma GmbH
Germany
Awegal inject
AWD.pharma GmbH & Co. KG
Germany
Katadolon inject
AWD.pharma GmbH & Co. KG
Germany
Katadolon Kinderzäpfchen
AWD.pharma GmbH & Co. KG
Germany
Katadolon Zäpfchen
AWD.pharma GmbH & Co. KG
Germany
Trancopal Dolo
AWD.pharma GmbH & Co. KG
Germany
Trancopal Dolo Suppositorien
AWD.pharma GmbH & Co. KG
Germany
Katadolon S long
AWD.pharma GmbH & Co. KG
Germany
Katadolon
AWD.pharma GmbH & Co. KG
Germany
Trancolong
AWD.pharma GmbH & Co. KG
Germany
Katadolon retard
AWD.pharma GmbH & Co. KG
Germany
Flupirtinmaleat Winthrop 400 mg Retardtabletten
AWD.pharma GmbH & Co. KG
Germany
Flupirtinmaleat-CT 100 mg Hartkapsel
CT Arzneimittel GmmbH
Germany
Flupin 100 mg Hartkapseln
CT Arzneimittel GmmbH
Germany
Dolokadin einmal täglich
Dr. Kade Pharmazeutische
Germany
Flupigamma 100 mg Hartkapseln
Hormosan Pharma GmbH
Germany
Flupirtinmaleat-Hormosan 100 mg Hartkapseln
Hormosan Pharma GmbH
Germany
Flupigil 100 mg Hartkapseln
MEDA Pharma GmbH & Co. KG
Germany
Flupigil 100 mg Hartkapseln
MEDA Pharma GmbH & Co. KG
Germany
Flupirtinmaleat Midas 100 mg Hartkapseln
Midas Pharma GmbH
Germany
Flupirtinmaleat-ratiopharm 100 mg Hartkapsel
ratiopharm GmbH
Germany
Miflumal 100 mg Hartkapseln
ratiopharm GmbH
Germany
Flupirtinmaleat Vitapharma 100 mg Hartkapseln
Vitapharma Generics GmbH
Germany
Flupivil 100 mg Hartkapseln
Vitapharma Generics GmbH
Germany
Flupirtinmaleat Viatris 100 mg Hartkapseln
Vitapharma Generics GmbH
Germany
Flupirtinmaleat Winthrop 100 mg Hartkapseln
Winthrop Arzneimittel GmbH
Germany
Efiret **
MEDA PHARMA S.p.A.
Italy
Katadolon 100 mg hard capsules
Teva Pharma B.V.
Latvia
Katadolon
Teva Pharma B.V.
Lithuania
Katadolon
Teva Pharmaceuticals Polska Sp. z o.o.
Poland
Metanor
Meda Pharma - Produtos Farmacêuticos, S.A.
Portugal
Katadolon
TEVA Pharmaceuticals
Slovak Republic
* This annex was previously amended on 28 June 2017. ** The marketing authorisation of Efiret has been withdrawn, therefore it has been removed from this list.
Jun 22, 2017 - authorised originator product (Aerius) and considered data included in the ... Non-clinical data reveal no special hazard for humans based on ...
Jan 11, 2018 - List of nationally authorised medicinal products. EMA/24585/2018. Page 2/8. Product Name (in authorisation country). MRP/DCP Authorisation number. National Authorisation. Number. MAH of product in the member state. Member State where p
Sep 20, 2016 - (R6) What kinds of safety data are required for applications ..... has to be demonstrated by using appropriate analytical data, for example.
Apr 28, 2017 - 2. The United Kingdom will then become a 'third country'. 3. Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. In view of the considerable uncertainties, in parti
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. ⢠Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. ⢠Feraccru (ferr
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...
The new EudraVigilance system and the electronic reporting of individual case ... the ISO/ICH E2B(R3) format: hands-on training course - October 2017 ... granted a conditional marketing authorisation on the basis of less complete clinical data ...
4 days ago - EMA/CAT/426129/2018. Page 2/17. Table of contents. 1. Introduction. 5. 1.1. Welcome and declarations of interest of members, alternates and ...
Sep 8, 2016 - 3-year report on Pharmacovigilance activities. Helen Lee, European Commission. â¢. Scanning the horizon for 2016 â 2018. Peter Arlett, EMA.
PCWP and HCPWP joint meeting - Sept 2016 - meeting documents. ⢠Workshop on identifying opportunities for 'big data' in medicines development and ...
Used for the management of hypovolaemia (low blood volume) caused by acute (sudden) blood loss .... EMA's Business Continuity Plan for Brexit published.
On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to enter our industry lounge, which you are welcome to utilise during your visit. The industry loung